Clavis' Hellebø takes the helm at Sir Chris Evans-backed ReNeuron

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Clavis' Hellebø takes the helm at Sir Chris Evans-backed ReNeuron

Biotech vet Olav Hellebø has taken the reins at ReNeuron, a regenerative medicines company that is slated to relocate to Wales next year. Hellebø had led Norway's Clavis, which experienced a couple of key setbacks in an attempt to develop new cancer therapies. Sir Chris Evans, the high-flying U.K. biotech entrepreneur, is one of the key players backing ReNeuron. Story

ReNeuron
Olav Hellebø joined as CEO.

Biotech

> Agilis Biotherapeutics appointed Dr. Mark Pykett as president and CEO. Release

> Nicole DeBerg joined the J. Craig Venter Institute as the organization's COO. Release

> Gregg Stetsko is leaving his post as vice president of research and development at Flamel Technologies ($FLML). Release

> Afferent Pharmaceuticals named Kathleen Sereda Glaub CEO. Release

> Darrell Lee has retired as vice president of MOCON ($MOCO), and Elissa Lindsoe was named as his successor. Release

> pSivida ($PSDV) has elected James Barry to its board of directors. Release

> To-BBB brought on Dr. Anders Harfstrand as the company's CEO. Release

> Second Genome appointed Karim Dabbagh as its chief scientific officer. Release

> Richard Gastineau joined Y-Prime as its chief operating officer. Release

> Abcam brought on Alan Hirzel to succeed Jonathan Milner as its CEO. Release

> Bruno Lucidi is the new CEO of Karolinska Development companies Aprea and Akinion Pharmaceuticals. Release

> Aptose Biosciences appointed Dr. Stephen Howell as its chief medical officer. Release

> CollPlant named Nadav Orr its vice president of research and development. Release

> RxTrials hired Yvonne McCracken as its vice president of clinical operations and compliance. Release

> Ignyta ($RXDX) appointed Robert Wild as its chief scientific officer and senior vice president of research. Release

> Batu Biologics named Dr. Hong Ma its chief scientific officer. Release

> Pivotal Therapeutics appointed Prakash Gowd as its chief financial officer. Release

Pharma

> Cyclacel Pharmaceuticals ($CYCC) has appointed Samuel Barker to its board of directors. Release

> Acucela appointed pharma exec Brian O'Callaghan as its new president and chief operating officer. He will also serve as interim CFO. Release

Biotech IT

> Jim Corrigan will assume the role of president and CEO at ERT. Corrigan has served as executive vice president and chief operating officer since August 2013. Release

Pharma Marketing

> Scott Peoples signed on as the vice president of marketing at Marrone Bio Innovations. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.